Divi's Laboratories Ltd. Share Price

Zydus completes Sterling Biotech API business buy

Zydus Lifesciences Limited (ZYDUSLIFE) has completed the acquisition of the API business of Sterling Biotech Limited. The deal follows completion of conditions precedent and closing date adjustments. The acquisition is based on the Business Transfer Agreement dated September 17, 2024. The transaction transfers the API business of Sterling Biotech to Zydus Lifesciences. The company has confirmed the closing of the deal after fulfilling all required conditions under the agreement. The key triggers are the completion of the Sterling Biotech API business acquisition and the fulfilment of conditions under the September 2024 agreement. This strengthens Zydus’s API manufacturing capabilities and product portfolio in fermentation-based ingredients. Peers such as Sun Pharma, Divi's Laboratories and Laurus Labs may face comparison on API capacity and backward integration. Near-term prices could react positively to the successful closure of the long-pending deal. Risks include integration challenges or slower-than-expected contribution from the acquired assets. Competitors listed: Sun Pharma, Divi's Laboratories, Laurus Labs. We have no financial interest in this news.

See More

An expanding channel breakout occurs with chart

An expanding channel breakout occurs when price moves within a widening channel, forming higher highs and lower lows, indicating increasing volatility and strong disagreement between buyers and sellers. When the price decisively breaks above the upper boundary of the expanding channel, it may signal a bullish breakout and the possibility of further upside momentum. Similarly, a breakdown below the lower boundary may indicate increasing selling pressure and potential downside continuation. Traders should closely monitor breakout volume, candle strength, and price confirmation, as expanding channels can also produce sharp reversals and false breakouts. chart is attached for the concept explanation.

See More

Divi's Laboratories NSE: DIVISLAB | Breakout watch

Divi's Laboratories NSE: DIVISLAB | Breakout watch | 2 November 2026 ₹9,780 +1.20% Last reported close: 30 October 2026. NSE India+1 Technical setup Parameter Level Immediate resistance ₹9,865 Breakout confirmation Above ₹9,865 Upside target 1 ₹10,000 Upside target 2 ₹10,200 Support ₹9,620 Positional support ₹9,500 Why it's on the radar - Trading near its 52-week high. - 30 October volume was approximately 10.75 lakh shares versus 3.95 lakh on the previous session. - RSI around 64 indicates positive momentum. - Price is above its 50-day and 200-day moving averages. ***** Upcoming trigger: Earnings are estimated for 4 November 2026. ***** My view: Positive, conditional breakout Wait for a sustained move above ₹9,865 with volume confirmation. Avoid fresh entries if it fails to cross resistance. Educational research idea, not a guaranteed return or personalized investment advice.

See More

Dr Reddy's sticks to 20%+ EBITDA margin for FY27.

Dr. Reddy's Laboratories Limited

has reiterated its FY27 EBITDA margin guidance of 20 percent and above. Q2 margins stood at 20.6 percent. The company maintained its full-year EBITDA margin outlook at 20 percent plus. Second-quarter margins came in at 20.6 percent. The guidance and reported figure show steady profitability for the pharma firm. Key numbers are the 20 percent plus FY27 EBITDA margin guidance and the 20.6 percent Q2 margin. These may support near-term interest in the stock on margin stability. Peers such as Sun Pharma, Cipla and Divi's Laboratories could face relative comparison on profitability trends. Risks include higher input costs or pricing pressure. Competitors listed: Sun Pharma, Cipla, Divi's Laboratories. We have no financial interest in this news.

See More

Jubilant Pharmova assigned IND AA+/Stable to ₹1,400 Cr NCDs.

Jubilant Pharmova Limited (JUBLPHARMA) has received a credit rating assignment from India Ratings and Research Pvt Ltd. The rating is for proposed non-convertible debentures amounting to ₹1,400 crore. The instrument is Proposed Non-Convertible Debentures of ₹1,400 crore. The assigned rating is IND AA+/Stable. The rating action is Assigned. The key trigger is the assignment of an IND AA+/Stable rating for the proposed ₹1,400 crore NCD issuance, which supports the company’s funding plans without equity dilution. This reflects a favourable view of its credit profile in the specialty pharmaceuticals and CDMO space. Peers such as Syngene International, Piramal Pharma, and Divi’s Laboratories may face comparison on balance-sheet strength and debt-raising capacity. Near-term prices could see a mild positive reaction on the rating assignment and funding visibility. Risks include the final terms of the NCD issuance or any subsequent pressure on leverage metrics. Competitors listed: Syngene International, Piramal Pharma, Divi’s Laboratories.

See More

Divi’s Laboratories: Geography and Capex Are the Real Story

Divi’s Laboratories (NSE : DIVISLAB) manufactures generic APIs and provides custom synthesis services to global pharmaceutical innovators. Its operations span established high-volume ingredients and complex molecules produced under long-term customer arrangements. What happened: In Q1FY27, Divi’s reported consolidated revenue of Rs 3,080 crore, up 27.8% year on year and 8.8% sequentially. Profit after tax rose 65.5% YoY to Rs 902 crore. Custom synthesis contributed around 60% of standalone revenue; generic APIs about 40%. Divi’s supplies 12 of the world’s 20 largest pharmaceutical companies. Three capex programmes backed by long-term supply commitments are under way, with some expected to reach commercial volumes in 12 to 24 months. Why it matters: Europe contributed Rs 6,311 crore of FY26 revenue, the largest geography by far. North America added Rs 1,360 crore and India Rs 1,147 crore. This Europe concentration creates currency and trade-policy exposure. Divi’s invested over Rs 1,500 crore in capex in FY26; Kadinada Unit 3 has six blocks operational and two under construction. The stock trades at a P/E of 80.4. What I am watching: JPMorgan maintained a Buy with a target of Rs 9,100; the stock closed at Rs 9,030 on 15 October, leaving almost no gap. The three long-term supply commitments are the most important forward signal. Whether those projects reach commercial volumes on schedule will determine the earnings trajectory over the next two to three years. My stance: Customer quality is exceptional and Q1FY27 numbers are strong. The capex cycle is large and supply commitments reduce demand uncertainty. Valuation at 80.4x reflects much of it. I do not hold a position in Divi’s Laboratories at the time of writing. This is not investment advice.

See More